Elite in Pseudohypoparathyroidism

Lars Rejnmark-Nielsen

Palle Juul Jensens Boulevard 82, 
Arhus, DK 
Elite in Pseudohypoparathyroidism
Palle Juul Jensens Boulevard 82, 
Arhus, DK 
OverviewLocationsClinical Research

Overview

Lars Rejnmark-Nielsen practices in Arhus, Denmark. Mr. Rejnmark-Nielsen is rated as an Elite expert by MediFind in the treatment of Pseudohypoparathyroidism. His top areas of expertise are Hypoparathyroidism, Hyperparathyroidism, Albright's Hereditary Osteodystrophy, Parathyroidectomy, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 241 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles and participated in 2 clinical trials in the study of Pseudohypoparathyroidism.

Gender
Male

Locations

Palle Juul Jensens Boulevard 82, Arhus, 8200, Denmark
Other Locations
Palle Juul Jensens Boulevard 165, Aarhus N, 8200, Denmark
Palle Juul Jensens Boulevard 99, Aarhus N, 8200, Denmark
Agro Food Park 48, Arhus, 8200, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Other
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological
Study Drug: rhPTH(1-84)
Study Phase: Phase 4
An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects With Hypoparathyroidism
An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects With Hypoparathyroidism
Enrollment Status: Terminated
Publish Date: October 07, 2022
Intervention Type: Biological
Study Phase: Phase 3
Impaired Quality of Life and Cognitive Function in Patients With Hypoparathyroidism Might be Explained by Disturbed Capillary Flow Patterns in the Brain
Impaired Quality of Life and Cognitive Function in Patients With Hypoparathyroidism Might be Explained by Disturbed Capillary Flow Patterns in the Brain
Enrollment Status: Completed
Publish Date: December 23, 2021
Intervention Type: Diagnostic test
An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism
An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism
Enrollment Status: Completed
Publish Date: May 25, 2021
Intervention Type: Drug
Study Phase: Phase 1
Physiologic Interactions Between the Adrenal- and the Parathyroid Glands
Physiologic Interactions Between the Adrenal- and the Parathyroid Glands
Enrollment Status: Completed
Publish Date: August 15, 2018
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 4
Characterization of Patients With Idiopathic Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism
Characterization of Patients With Idiopathic Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism
Enrollment Status: Unknown
Publish Date: August 07, 2018
View 6 Less Clinical Trials

241 Total Publications

Advances in the Clinical Management of Parathyroid Disorders: Report from the 2024 Workshop by the ESE Educational Program on Parathyroid Disorders.
Advances in the Clinical Management of Parathyroid Disorders: Report from the 2024 Workshop by the ESE Educational Program on Parathyroid Disorders.
Journal: European journal of endocrinology
Published: July 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rejnmark-Nielsen's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 14 Advanced Conditions
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile